Phaseline

Targets › MARV

MARV: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: the race on MARV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Albert B. Sabin Vaccine InstitutecAd3-Marburg Vaccine
chimpanzee adenovirus Type 3-vectored vaccine expressing Marburg wild type glycoprotein fr
MARVPhase 2Marburg Virus Disease–
International AIDS Vaccine InitiativerVSV∆G-MARV-GP
Recombinant vesicular stomatitis virus expressing Marburg virus glycoprotein
MARVPhase 1Marburg Virus DiseaseApr 2027

Conditions

Marburg Virus Disease (2)

Modalities

protein or peptide (1), other (1)

Companies

International AIDS Vaccine Initiative (1) Albert B. Sabin Vaccine Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.